Figure 5.

Oronasal investigation (in seconds) of the demonstrator by the observer female mice in all phases of the estrous cycle during the 30-min social interaction with their demonstrator. In (a), observer mice had received either no treatment (n=23) or an intraperitoneal injection of either saline vehicle (n=25) or the D1-type antagonist SCH23390 at 0.01 mg/kg (n=25), 0.05 mg/kg (n=24), and 0.1 mg/kg (n=26). In (b), observer mice had received either no treatment (n=8) or an intraperitoneal injection of either saline vehicle (n=20) or the D2-type antagonist raclopride at 0.1 mg/kg (n=19), 0.3 mg/kg (n=20), and 0.6 mg/kg (n=19). In (c) the pooled untreated observer mice from (a) and (b) were either in diestrus (n=6), proestrus (n=13), or estrus (n=10) on the day of testing. ^**p<0.001; ^*p<0.01; p<0.05; in comparison to the saline-treated control group.